title: Cytomegalovirus infection after renal transplantation: selective prophylaxis and treatment.
abstract: We have reviewed our experience in selective cytomegalovirus (CMV) infection prophylaxis and treatment in our renal transplant population. Between 1996 and 2001, 263 cadaveric renal transplant recipients had at least 6 months follow up. Immunosuppression was based on cyclosporine Neoral (n=108) or tacrolimus (n=155). CMV infection prophylaxis (oral acyclovir or gancyclovir at half usual doses) was only prescribed in recipients receiving a CMV positive ve kidney and in recipients treated with OKT3. CMV infection was diagnosed by a positive pp65 antigenemia upon appearance of CMV-related symptoms, leading to specific treatment (IV ganciclovir) only if symptoms were intense or there was visceral involvement. Thus, no preemptive treatment or programmed or periodic antigenemia was performed in any case. Nineteen episodes of symptomatic CMV infection were diagnosed (prevalence 7.2%). The frequency was similar for all immunosuppressive regimens. Only 9 of 19 (47%) of patients were given IV ganciclovir; the others were not treated. All patients survived without apparent complications, relapses, or recurrences. No oral gancyclovir was delivered after IV treatment. Our CMV prophylaxis protocol was limited to high-risk patients, using lower gancyclovir dosages than those usually advocated. It does not include programmed or scheduled search for CMV antigenemia in asymptomatic renal transplant patients. Despite these factors, our CMV infection rate and severity were similar to those reported with more aggressive protocols, with extended prophylaxis, preemptive therapy, or intense surveillance.
authors.affiliation: Servicios de Nefrología y Urología, Hospital Ramón y Cajal, Madrid, Spain. jpascual.hrc@salud.madrid.org
authors.forename: J
authors.initials: J
authors.lastname: Pascual
authors.forename: M C
authors.initials: MC
authors.lastname: Alarcón
authors.forename: R
authors.initials: R
authors.lastname: Marcén
authors.forename: F J
authors.initials: FJ
authors.lastname: Burgos
authors.forename: A
authors.initials: A
authors.lastname: Tato
authors.forename: M T
authors.initials: MT
authors.lastname: Tenorio
authors.forename: F
authors.initials: F
authors.lastname: Liaño
authors.forename: J
authors.initials: J
authors.lastname: Ortuño
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015774:Ganciclovir; D000212:Acyclovir